| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754550 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 7 Pages |
Abstract
The combination of sequential azacitidine and midostaurin is safe and tolerable with response rates comparable with azacitidine alone and should be studied further in FLT3 mutation-positive AML.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Brenda W. Cooper, Tamila L. Kindwall-Keller, Michael D. Craig, Richard J. Creger, Mehdi Hamadani, William W. Tse, Hillard M. Lazarus,